Skip to main content

Table 1 Blood parameters and patient demographic measured in CFS/ME patients and NFC groups

From: Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation

 

NFC (n = 9)

CFS/ME (n = 8)

P value

Age (years)

37.56 ± 11.06

48.63 ± 15.69

0.503

Gender

Male n(%)

3(33.3)

1 (12.5)

 

Female n(%)

6 (66.7)

7 (87.5)

 

Pathology

White Cell Count (× 109/L)

5.94 ± 1.61

5.45 ± 1.09

0.664

Neutrophils (×109/L)

3.54 ± 1.49

3.36 ± 0.82

0.847

Lymphocytes (× 109/L)

1.87 ± 0.38

1.70 ± 0.49

0.248

Monocytes (× 109/L)

0.32 ± 0.11

0.32 ± 0.06

0.962

Eosinophils (× 109/L)

0.18 ± 0.09

0.18 ± 0.12

0.885

Platelet (× 109/L)

240.78 ± 47.65

258.88 ± 37.13

0.413

Haemoglobin (g/L)

132.67 ± 8.51

135.38 ± 7.82

0.384

Haematocrit

0.37 ± 0.10

0.42 ± 0.03

0.191

Red Cell Count (× 1012/L)

4.53 ± 0.34

4.49 ± 0.34

0.923

MCV fl

89.67 ± 2.74

92.88 ± 5.11

0.222

  1. Results from white and red blood cell parameters measured in CFS/ME and control groups. Comparisons of blood parameters between the CFS/ME and NFC revealed no significant differences. No significant differences were observed in patient age distribution. Data presented as mean ± standard deviation. Abbreviations: NFC, non-fatigued controls; CFS/ME, chronic fatigue syndrome; ME, Myalgic encephalomyelitis